Your shopping cart is currently empty

Bicyclomycin benzoate, an antibiotic, exhibits activity against a broad spectrum of Gram-negative/Gram-positive bacteria.


| Description | Bicyclomycin benzoate, an antibiotic, exhibits activity against a broad spectrum of Gram-negative/Gram-positive bacteria. |
| In vitro | Bicyclomycin interferes with the biosynthesis of lipoprotein and its assembly to peptidoglycan in the cell envelope of E. coli. At the lethal level, Bicyclomycin is shown to inhibit the synthesis of RNA and protein in the growing cells of E. coli 15 THU [1]. Bicyclomycin targets the rho transcription termination factor in Escherichia coli. Bicyclomycin can disrupt the rho molecular machinery thereby leading to a catastrophic effect caused by the untimely overproduction of proteins not normally expressed constitutively, thus leading to a toxic effect on the cells [2]. The inhibition of rho poly(C)-stimulated hydrolysis of ATP by Bicyclomycin has been found to proceed by a non-competitive, reversible pathway with respect to ATP (Ki: 20 μM) [3]. |
| In vivo | Following a single intramuscular administration of Bicyclomycin at a dosage of 50 mg/kg in rats, the compound exhibits a low rate of excretion. It is well distributed across different tissues, with the peak concentration recorded in the kidneys at a level of 100 mg/kg [4]. |
| Synonyms | FR2054, FR 2054 |
| Molecular Weight | 406.39 |
| Formula | C19H22N2O8 |
| Cas No. | 37134-40-0 |
| Smiles | C[C@](O)(COC(=O)c1ccccc1)[C@H](O)[C@@]12NC(=O)[C@@](O)(NC1=O)C(=C)CCO2 |
| Relative Density. | 1.49 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (196.86 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (8.12 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.